Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics

Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics: Biocon Biologics India, a subsidiary of Biocon, and digital therapeutics company Voluntis have recently announced a global collaboration agreement between Biocon Biologics’ subsidiary Biocon Sdn. Bhd.

VARINDIA- INDIA'S FRONTLINE IT MAGAZINE

Comments

Popular posts from this blog

OpenAI unveils new o3 and o3 mini models, set for 2024 launch

PhysicsWallah transitions to public entity in preparation for 2025 IPO